Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ) (CALT) Stock Overview

Explore Calliditas Therapeutics AB (publ)’s financial performance, market position, analyst ratings, and future outlook.

CALT●NASDAQ
HealthcareBiotechnology
$40.000
$0.04(0.10%)
U.S. Market opens in 19h 57m

Calliditas Therapeutics AB (publ) (CALT)

Meyka AI Score

Z

Key Financials

Market Cap2.1B
P/E Ratio-22.87
EPS (TTM)$-1.76
ROE-0.85%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$50.22

CALT Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Calliditas Therapeutics AB (publ) (NASDAQ: CALT) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Calliditas Therapeutics AB (publ)'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of CALT on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $50.22 for the NASDAQ listing.

Key metrics behind Calliditas Therapeutics AB (publ)'s NASDAQ-traded stock include a P/E ratio of -22.87 and a market capitalization of 2.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of CALT on the NASDAQ.

Price Performance (NASDAQ: CALT)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
3.12%
6-Month Change
113.90%
Year-to-Date (YTD) Change
60.000%
1-Year Change
129.16%
3-Year Change
75.06%
5-Year Change
104.08%
All-Time (Max) Change
104.08%

Contact Information

https://www.calliditas.se
46 84 11 30 05
Kungsbron 1, D5, Stockholm, NaN, 111 22

Company Facts

2,220 Employees
IPO DateJun 5, 2020
CountrySE

Frequently Asked Questions